NeuroVive’s board of directors has appointed Erik Kinnman, who has extensive industry and research experience and has held a number of senior leadership positions in companies such as AstraZeneca and Sobi, as the new CEO of the company. He assumed the role on March 14.
“The NeuroVive Board and I are confident that Erik Kinnman is the right person to lead the company, its strategy, and leverage the opportunities. The combination of his strategic vision and medical expertise is an excellent fit with NeuroVive’s strategy refocused towards R&D”, commented Gregory Batcheller, Chairman of the NeuroVive Board of Directors.
Erik Kinnman succeeds Jan Nilsson, who will resume his position as COO after making significant and much appreciated contributions as the company’s interim CEO. Significant milestones achieved under his leadership include a strong partnership with the British partner Isomerase as well as a research collaboration with University of Pennsylvania in the area of traumatic brain injury.